Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis
Malaviya, R.; Sun, Y.; Tan, J.K.; Magliocco, M.; Gottlieb, A.B.
Journal of Drugs in Dermatology Jdd 5(9): 890-893
2006
ISSN/ISBN: 1545-9616 PMID: 17039656 Document Number: 9172
Infliximab demonstrates high efficacy in treating psoriasis in a high proportion of patients. In this report we demonstrate induction of plaque (T cells, dendritic cells) and peripheral blood (T cells, monocytes) leukocyte apoptosis following a single infliximab infusion in a psoriasis patient.
Document emailed within 1 workday
Related Documents
Szychta, M.; Wiernicka, A.; Dądalski, M.; Landowski, P.; Klincewicz, B.; Karolewska-Bochenek, K.; Czaja-Bulsa, G.ży.; Jarocka-Cyrta, E.; Korczowski, B.; Sladek, M.; Kierkus, J. 2016: Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study Developmental Period Medicine 20(3): 205-211Kalb, R.E.; Blauvelt, A.; Sofen, H.L.; Chevrier, M.; Amato, D.; Calabro, S.; Wang, J.; Schenkel, B.; Gottlieb, A.B. 2013: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial Journal of Drugs in Dermatology: Jdd 12(8): 874-880
Bonifati, C.; Carducci, M.; Mussi, A.; D'auria, L.; Ameglio, F. 1997: IL-1 alpha, IL-1 beta and psoriasis: conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or non-lesional extracts of whole skin Journal of Biological Regulators and Homeostatic Agents 11(4): 133-136
Sri, J.C.; Tsai, C.L.; Deng, A.; Gaspari, A.A. 2007: Osteomyelitis occurring during infliximab treatment of severe psoriasis Journal of Drugs in Dermatology: Jdd 6(2): 207-210
Mahiques Santos, L.; Martínez Menchón, T.; Sánchez Carazo, Jé.Luis.; Fortea Baixauli, Jé.Miguel. 2005: Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy Medicina Clinica 125(4): 159
Krishnan, R.S.; Hsu, S. 2004: Serum sickness due to infliximab in a patient with psoriasis Journal of Drugs in Dermatology: Jdd 3(3): 305-308
Alabed, I.B.; Qushmaq, K.A.; Khan, M.A. 2010: Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis Saudi Medical Journal 31(9): 1054-1056
West, C.; Narahari, S.; O'Neill, J.; Davis, S.; Huynh, M.; Clark, A.; Boles, A.; Feldman, S.R. 2013: Adherence to adalimumab in patients with moderate to severe psoriasis Dermatology Online Journal 19(5): 18182
Price, J.; Bhosle, M.; Feldman, S.R.; Balkrishnan, R. 2007: Outcomes associated with the use of biologic agents in moderate to severe psoriasis Journal of Drugs in Dermatology: Jdd 6(3): 259-267
Opel, D.; Economidi, A.; Chan, D.; Wasfi, Y.; Mistry, S.; Vergou, T.; Antoniou, C.; Sofen, H. 2012: Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab Journal of Drugs in Dermatology: Jdd 11(12): 1498-1501
Kircik, L.; Lebwohl, M.G.; Del Rosso, J.Q.; Bagel, J.; Stein Gold, L.; Weiss, J.S. 2013: Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis Journal of Drugs in Dermatology: Jdd 12(12): 1404-1410
Bagel, J. 2011: Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis Journal of Drugs in Dermatology: Jdd 10(4): 366-371
Jarratt, M.; Breneman, D.; Gottlieb, A.B.; Poulin, Y.; Liu, Y.; Foley, V. 2004: Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis Journal of Drugs in Dermatology: Jdd 3(4): 367-373
Han, C.; Lofland, J.H.; Zhao, N.; Schenkel, B. 2011: Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis Journal of Drugs in Dermatology: Jdd 10(8): 843-850
Kircik, L.H.; Liu, C.; Goffe, B.S. 2008: Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy Journal of Drugs in Dermatology: Jdd 7(10): 947-952
Brodmerkel, C.; Wadman, E.; Langley, R.G.; Papp, K.A.A.; Bourcier, M.; Poulin, Y.; Ho, V.; Guenther, L.; Kunynetz, R.; Nigen, S.; Vender, R.; Wasel, N.; Hsu, M.-C.; Szapary, P. 2013: Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use Journal of Drugs in Dermatology: Jdd 12(10): 1122-1129
Dennehy, E.B.; Zhang, L.; Amato, D.; Goldblum, O.; Rich, P. 2016: Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3 Journal of Drugs in Dermatology: Jdd 15(8): 958-961
Sobell, J.M.; Kalb, R.E.; Weinberg, J.M. 2009: Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents Journal of Drugs in Dermatology: Jdd 8(2): 147-154
Stein Gold, L.; Kircik, L.H.; Pariser, D.; Sugarman, J.L.; Lin, T.; Kang, R.; Pillai, R. 2018: Rapid Onset of Action in Patients with Moderate-to-Severe Plaque Psoriasis with Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Journal of Drugs in Dermatology: Jdd 17(8): 863-868
Pariser, D.M.; Green, L.J.; Stein Gold, L.; Sugarman, J.L.; Lin, T.; Pillai, R. 2018: Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy Journal of Drugs in Dermatology: Jdd 17(7): 723-726